Please login to the form below

Not currently logged in
Email:
Password:

pharma payments

This page shows the latest pharma payments news and features for those working in and with pharma, biotech and healthcare.

Roche builds on Immunocore ImmTAC deal

Roche builds on Immunocore ImmTAC deal

Immunocore will receive $100m in upfront and near-term milestone payments from Genentech, which has the option to co-develop IMC-C103C through commercialisation. ... Beyond that, Genentech can also fully license the product in return for royalty and

Latest news

  • UK pharma Code of Practice to change with digital times UK pharma Code of Practice to change with digital times

    well as updates to how healthcare professionals are asked to disclosure payments from pharma. ... Earlier this year, Martindale Pharma, Pierre Fabre, Janssen and Pharmasure were all named in adverts following serious breaches the Code.

  • UK unveils plans for bigger medicines price squeeze UK unveils plans for bigger medicines price squeeze

    The system works by pharma companies making payments based on a percentage of their overall UK sales - this currently stands at 7.8% - but the government has now concluded that this ... period. It also predicts that reduced revenue for pharma companies

  • Boehringer bolsters NASH pipeline with $201m Dicerna deal Boehringer bolsters NASH pipeline with $201m Dicerna deal

    It stands to receive $201m in upfront and milestone payments from the privately-held German pharma group, plus royalties on any eventual sales. ... NASH is a hot topic in pharma development at the moment, with a host of companies vying to bring forward

  • Nearly half of HCPs refuse to disclose pharma payments Nearly half of HCPs refuse to disclose pharma payments

    A sizeable minority of healthcare professionals (HCPs) have not consented to disclose payments received by pharma companies in the UK, according to the first data from the new Disclosure UK database. ... All told 55% of HCPs had disclosed payments or

  • UK pharma HCP payment database goes live UK pharma HCP payment database goes live

    Two-thirds of payments related to research and development work. UK pharma has published details of the payments and benefits in kind it provides to doctors, nurses and pharmacists as ... That work, led by EFPIA and following on from similar efforts in

More from news
Approximately 1 fully matching, plus 34 partially matching documents found.

Latest Intelligence

  • ‘Trust me, I’m from the pharmaceutical industry?’ ‘Trust me, I’m from the pharmaceutical industry?’

    A number of countries across the world insist that payments between pharma and healthcare professionals (HCPs) are made public. ... However, it’s now thought only 55% of HCPs actually revealed the payments they received.

  • Could EFPIA's new code boost pharma's reputation? Could EFPIA's new code boost pharma's reputation?

    The “eyes of the world will be upon the industry” from next year as disclosure of payments to doctors in Europe becomes mandatory - and pharma must embrace this change to help ... He pointed to a number of recent anti-pharma headlines from UK

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Grace Communications

Grace Communications is an award winning, independent, full service, creative communications agency specialising in solving problems for healthcare brands....

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics